These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17580365)

  • 21. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved survival with drug-eluting stent implantation in comparison with bare metal stent in patients with severe left ventricular dysfunction.
    Gioia G; Matthai W; Benassi A; Rana H; Levite HA; Ewing LG
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):392-8. PubMed ID: 16892436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
    Hannan EL; Racz M; Walford G; Holmes DR; Jones RH; Sharma S; Katz S; King SB
    JACC Cardiovasc Interv; 2008 Apr; 1(2):129-35. PubMed ID: 19463290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronary artery disease: Complex coronary disease in the post-SYNTAX era.
    Tarantini G
    Nat Rev Cardiol; 2009 Jun; 6(6):397-8. PubMed ID: 19471286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. If I've heard it once, I've heard it (not yet) a hundred times.
    Butman SM
    Catheter Cardiovasc Interv; 2011 Mar; 77(4):502. PubMed ID: 21351224
    [No Abstract]   [Full Text] [Related]  

  • 26. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stent strut fracture: seeing is believing.
    Carter AJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):619-20. PubMed ID: 18360854
    [No Abstract]   [Full Text] [Related]  

  • 28. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
    Qian J; Chen Z; Ma J; Ge J
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
    Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial.
    Berger A; Stauffer JC; Seydoux C; Siegenthaler M; Benoît A; Goy JJ
    Catheter Cardiovasc Interv; 2007 Aug; 70(2):163-6. PubMed ID: 17630653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Percutaneous coronary intervention in nonagenarians: age before beauty?
    Bhatt DL
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):531-2. PubMed ID: 18307234
    [No Abstract]   [Full Text] [Related]  

  • 34. Oral sirolimus after bare metal stent implantation: a glimpse to the future.
    Mieres J
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):158-9. PubMed ID: 20931667
    [No Abstract]   [Full Text] [Related]  

  • 35. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?
    Finn AV; Nakazawa G; Kolodgie FD; Virmani R
    JACC Cardiovasc Interv; 2009 Apr; 2(4):300-2. PubMed ID: 19463440
    [No Abstract]   [Full Text] [Related]  

  • 37. DES editorial. Is there a survival benefit?
    Thomas DM
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):644-5. PubMed ID: 18360857
    [No Abstract]   [Full Text] [Related]  

  • 38. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
    Cho Y; Yang HM; Park KW; Chung WY; Choi DJ; Seo WW; Jeong KT; Chae SC; Lee MY; Hur SH; Chae JK; Seong IW; Yoon JH; Oh SK; Kim DI; Park KS; Rha SW; Jang YS; Bae JH; Hong TJ; Cho MC; Kim YJ; Jeong MH; Kim MJ; Park SK; Chae IH; Kim HS;
    JACC Cardiovasc Interv; 2010 May; 3(5):498-506. PubMed ID: 20488406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-eluting stent endothelium: presence or dysfunction.
    van Beusekom HM; Serruys PW
    JACC Cardiovasc Interv; 2010 Jan; 3(1):76-7. PubMed ID: 20129573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.